Resource Center
This video delves into the biology of the biomarkers utilized in the aGVHD Algorithm assays, providing a foundational understanding of their role in assessing aGVHD risk. It explains how MAGIC Algorithm Probability (MAP) testing classifies patients based on their long-term risk of severe graft versus host disease (GVHD) and non-relapse mortality, focusing on various patient stages: pre-symptomatic, symptom onset, and post-treatment after hematopoietic cell transplantation (HCT). Additionally, the series covers the interpretation of MAPs as response biomarkers, helping clinicians gauge treatment efficacy. Finally, it presents case studies that recommend treatment approaches guided by MAPs, demonstrating the practical application of these insights in clinical settings.
This bi-lateral lung transplant recipient is a 65 year-old male patient who received his lung transplant due to end-stage lung disease secondary to non-CF bronchiectasis. The donor and recipient CMV serostatus is D+/R+. The patient’s initial peri-operative course was complicated by difficult explant, primary graft dysfunction, respiratory failure requiring prolonged mechanical ventilation, renal insufficiency and recurrent infectious concerns, including pseudomonas and stenotrophomonas pneumonias.